News

8 Apr 2026

Second U.S. Patent from PTSD Programme

8 Apr 2026

Second U.S. Patent from PTSD Programme

8 Apr 2026

Second U.S. Patent from PTSD Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

22 Dec 2025

Research and Development Update – Q4 2025

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

3 Dec 2025

SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

27 Oct 2025

Solvonis appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

16 Oct 2025

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

Load More